News
HQL
19.25
-1.94%
-0.38
Weekly Report: what happened at HQL last week (0720-0724)?
Weekly Report · 5h ago
10 Best CEFs This Month: Average Yield Of Near 10% (July 2026)
Seeking Alpha · 2d ago
Weekly Report: what happened at HQL last week (0713-0717)?
Weekly Report · 07/20 09:30
Weekly Report: what happened at HQL last week (0706-0710)?
Weekly Report · 07/13 09:30
RIV: A Good Diversifier For A Portfolio
Seeking Alpha · 07/11 05:07
Weekly Report: what happened at HQL last week (0629-0703)?
Weekly Report · 07/06 09:32
THQ: A Solid Healthcare Fund For 2026
Seeking Alpha · 07/03 15:01
Press Release: Aberdeen Investments U.S. -2-
Dow Jones · 06/30 20:17
Press Release: Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
Dow Jones · 06/30 20:17
Weekly Report: what happened at HQL last week (0622-0626)?
Weekly Report · 06/29 09:30
Weekly Report: what happened at HQL last week (0615-0619)?
Weekly Report · 06/22 09:33
Weekly Report: what happened at HQL last week (0608-0612)?
Weekly Report · 06/15 09:34
Weekly Report: what happened at HQL last week (0601-0605)?
Weekly Report · 06/08 09:32
Weekly Report: what happened at HQL last week (0525-0529)?
Weekly Report · 06/01 09:34
BMEZ: Removal Of Options Should Improve Performance (Rating Upgrade)
Seeking Alpha · 05/28 09:40
Press Release: ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
Dow Jones · 05/27 22:40
Weekly Report: what happened at HQL last week (0518-0522)?
Weekly Report · 05/25 09:35
abrdn Life Sciences Investors Q1 2026 Commentary
Seeking Alpha · 05/20 15:40
HQL: Attractive Outlook With Growth Of GLP-1 Market
Seeking Alpha · 05/19 12:31
Weekly Report: what happened at HQL last week (0511-0515)?
Weekly Report · 05/18 09:35
More
Webull provides a variety of real-time HQL stock news. You can receive the latest news about abrdn Life Sciences Investors through multiple platforms. This information may help you make smarter investment decisions.
About HQL
Tekla Life Sciences Investors (the Fund) is a diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in the United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, agriculture, and environmental management. The Fund invests primarily in securities of public and private companies, which have potential for above-average growth. The Fund may invest up to 20% of its net assets in securities of foreign issuers, located primarily in Western Europe, Canada and Japan, and securities of the United States issuers that are traded primarily in foreign markets. The Fund's investment advisor is Tekla Capital Management LLC.